ImmunoPrecise Antibodies Ltd [IPA] stock is trading at $1.48, down -11.11%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IPA shares have gain 12.98% over the last week, with a monthly amount glided 126.30%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ImmunoPrecise Antibodies Ltd [NASDAQ: IPA] stock has seen the most recent analyst activity on December 02, 2022, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $9. Previously, The Benchmark Company started tracking the stock with Buy rating on October 25, 2021, and set its price target to $12.
ImmunoPrecise Antibodies Ltd [IPA] stock has fluctuated between $0.27 and $2.01 over the past year. ImmunoPrecise Antibodies Ltd [NASDAQ: IPA] shares were valued at $1.48 at the most recent close of the market.
Analyzing the IPA fundamentals
ImmunoPrecise Antibodies Ltd [NASDAQ:IPA] reported sales of 17.42M for the trailing twelve months, which represents a drop of -5.89%. Gross Profit Margin for this corporation currently stands at 0.51% with Operating Profit Margin at -0.55%, Pretax Profit Margin comes in at -2.13%, and Net Profit Margin reading is -1.92%. To continue investigating profitability, this company’s Return on Assets is posted at -1.01, Equity is -1.48 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.51.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4033 points at the first support level, and at 1.3267 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6133, and for the 2nd resistance point, it is at 1.7467.
Ratios To Look Out For
For context, ImmunoPrecise Antibodies Ltd’s Current Ratio is 2.32. Further, the Quick Ratio stands at 2.11, while the Cash Ratio is 1.45. Considering the valuation of this stock, the price to sales ratio is 3.89, the price to book ratio is 3.90.
